Lindsay Pike

Since starting her training, Lindsay has gained experience in patent drafting, prosecution and opposition of patent applications in the UK, Europe and worldwide. She has worked on cases from a variety of clients, including multinational companies, SMEs and academic institutions, across the chemical and pharmaceutical fields. She has experience in inventions relating to gene therapies, antibodies, vaccines, chimeric antigen receptors, genetically-modified plants, food enzymes, and even anti-wrinkle creams (amongst others).

Lindsay qualified as a UK Patent Attorney in 2023 after sitting the Final Diploma examinations in October 2022. She was awarded the Ballantyne Prize by the UK Chartered Institute of Patent Attorneys for the highest mark in the Validity & Infringement (FD4/P6) examination.

Lindsay has studied human, microbial and plant genetics as part of her BSc genetics at Cardiff University (2015), when she also gained experience in rare plant genetics research for conservation purposes at the Royal Botanic Gardens, Kew, London. She then completed a PhD in microbiology and genomics at the University of Cambridge (2020), and a PGCert in Intellectual Property Law at Queen Mary University of London (2021).

Her doctoral research involved identifying novel bacteria and antibiotic resistance genes from the intestinal microbiome.

Lindsay is a member of the Chartered Institute of Patent Attorneys (CIPA) and a student member of the European Patent Institute (EPI).